Form 4: Generation Bio CFO's Holdings Zeroed Post-Merger

Generation Bio Co. Chief Financial Officer Kevin John Conway's beneficial ownership of common stock and stock options was eliminated following the company's merger with XOMA Royalty Corporation.

Summary

• Generation Bio Co. completed its merger with XOMA Royalty Corporation, effective February 9, 2026.
• Generation Bio Co. is now a wholly-owned subsidiary of XOMA Royalty Corporation.
• Common stock shares were exchanged for $4.2913 cash per share and one non-tradeable contingent value right (CVR) per share, with an estimated maximum contingent consideration of $25.01 per CVR.
• Kevin John Conway, CFO, disposed of 2,072 shares of common stock.
• All outstanding and unexercised stock options with an exercise price equal to or greater than the $4.2913 cash amount were cancelled for no consideration.
• Kevin John Conway's beneficial ownership of common stock and stock options is now zero.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative event for the reporting person due to the cancellation of a significant number of stock options for no consideration, indicating a loss of potential value from these equity incentives.

Positives

• The merger provided Generation Bio Co. stockholders with a cash payment of $4.2913 per share and a contingent value right (CVR) with an estimated maximum value of $25.01 per CVR.

Negatives

• Kevin John Conway's stock options, which had exercise prices significantly above the merger's cash consideration, were cancelled for no consideration.
• The reporting person no longer holds any beneficial ownership in Generation Bio Co.

Future Outlook

No specific future outlook or guidance is provided in this Form 4.

Industry Context

StockSavvy.ai notes that mergers and acquisitions often lead to significant changes in executive compensation structures, particularly regarding equity holdings. The cancellation of out-of-the-money options is a common outcome in such transactions, reflecting the pre-merger valuation and the terms negotiated for the acquisition.

Comparison to Industry Standards

• In similar biotech or pharmaceutical mergers, it is standard practice for equity awards, especially stock options, to be treated according to the merger agreement.
• Options with exercise prices significantly above the acquisition price, such as those held by Mr. Conway (ranging from $9.255 to $316.9 compared to a $4.2913 cash component), are typically cancelled for no consideration, aligning with common industry benchmarks for M&A transactions where the target company's valuation is below the strike price of certain equity incentives.

Stakeholder Impact

• Shareholders: Received $4.2913 cash per share plus one CVR with an estimated maximum value of $25.01 per CVR.
• Employees (specifically option holders): Those with options having exercise prices above the cash consideration saw their options cancelled for no consideration.

Key Dates

Keywords

Generation Bio Co., GBIO, XOMA Royalty Corporation, Merger, Form 4, Beneficial Ownership, Stock Options, Contingent Value Right, CFO, Kevin John Conway